BioCryst Pharmaceuticals, Inc.’s berotralstat has been given the go-ahead for pre-approval use in the UK for preventing recurrent attacks of the rare and potentially life-threatening disease, hereditary angioedema (HAE), under the Early Access to Medicines Scheme (EAMS).
The Medicines and Healthcare products Regulatory Agency has published a positive scientific opinion stating that berotralstat (Orladeyo) can be used...








